INDGLOBL NEXTGEN MEDICARE LIMITED

CINO74900TN2015PLC100070

PROPOSAL INVITING RS.90 CR FUNDS TO LAUNCH PRECISION

DIAGNOSTIC INFORMATICS CENTER FIRST OF ITS KIND IN INDIA

REGD OFF 28/237E IV AVENUE INDRA NAGAR CHENNAI 600 020

 PROFILE/ACTIVITIES

M/s. Indglobl Nextgen Medicare Limited was promoted by Dr. R. Anandapadmanaban,

P.hD., FPTS, FHMS, Senior Scientist, (profile – Annexure-1) to venture into R&D
activities in Preventive Health Care and Hygiene, and registered with ROC Chennai, on
13/4/2015. He is The Chairman and Managing Director of INML.

BOARD OF DIRECTORS

DR. R. ANANDAPADMANABAN Ph.D., F.H.M.S., F.P.T.S. (USA)

DR. MARY RINI GEORGE M.B.B.S., (M.D.,)PATH
DR. ARUN VELKUMAR

UNIQUE ACHIEVEMENTS OF DR R ANANDAPADMANABAN Ph.D., F.H.M.S., F.P.T.S. (USA)

 Perhaps the only scientist in India who has been a scientific member of more
than seven different scientific societies relevant to medicine.
 Work formed the face cover of the journal Transplantation.
 Protocol formulated is used in cancer treatment and forms a part of medical
tests in Oncology
 The first person to sequence the BAC60L21 in full before the publishing of the
draft sequence of the human genome.
 First Person to sequence the rat TCR locus and produce a fine map of the
same for work focusing on allogeneic T cell clonal response in a Kidney Tx
model.
 Possesses the only mathematically proven analysis on cancer cell chimerism
in the world that is used to identify cancer cells in PET-negative patience with
metastasis.
To begin with, NML started researching in

 Systematic R & D on the molecular diagnostics of inherited genetic disorders

using yesteryear technology applicable to India with a radically reduced cost.
 Development and dry run of these diagnostics in our COLLABORATORY space.
 Development of a simple B & W model of canine to assess tolerance in skin
transplantation settings native to India, through six generations of breeding &
selection.
 Systematic R & D of type 2 diabetes patients over the past 15 years to assess
islet transplantation technology to facilitate cadaver islet transplantation in
India.
 R & D on the diversity of HLA alleles in India which forms the basis of a rapid
screen of a cross-section of a whole population to derive individuals matching
the tissue type of any particular

It is quite common for any R&D company to have a large outflow initially and INML
crossed this risky phase successfully with OWN funds, depicting the absolute
confidence and dedication of its promoters, managed to remain a nil-debt company
in the first 8 years, sitting on an equity base of around 55 CR. It is also common that
any R&D company’s explosive growth shall commence only from its first commercial
launch. And, INML reached this cross-juncture – launching PIC, Precision Informatics
Diagnostics Centers, the first of its kind, PAN India.
PRECISION INFORMATICS-DIAGNOSTIC CENTERS

INML has extensive research content, but for the scope of this report, please find
attached a one-page introduction (Annexure – 2).

In simple terms, the diagnostic process can be termed as "many tests in one”. For
example, for many multi-factor Genetically Inherited "Lifestyle Diseases" like
Obesity, Insomnia, Diabetes, etc., one can get an accurate diagnosis done about one's
susceptibility and predisposition to the disease. Discovery of susceptibility by the
patient allows better options to her/him on prevention of the disease per se and in
certain cases better management of the disease at a fractional cost. In a host of 900
inherited diseases, early detection can also lead to the eradication of the disease;
timely detection (for example – boy and girl getting diagnosed before marriage) can
help in ensuring their kids don't have such a disease; also such diseased conceptus
(Foetus/ baby) can be treated “in utero” by "allogeneic efficient cells" which
complement "the deficient cells" with the genetic mutation, such that over time, the
entire deficiency can be overcome partially or fully. In short, such diagnostics play
an inevitable role in wiping out such or similar diseases and extend invaluable
human lives, and thus, over some time, shall result in a disease-free India, the first
of its kind in the world.

MISSION
Providing the best preventive medical care to every Indian citizen

VISION
India to become a first disease-free country in the world by 2033
A “SAMPLE” REPRESENTATIVE LIST OF ALARMING COMMON DISEASES IN INDIA

Disease Description Source

Diabetes Million diabetics ICMR

136 Million pre-diabetics

High Blood Pressure 315 Million ICMR

Obesity 41 Million NFHS

survey

All Cancers (non-hematopoietic) 1 in 10 diagnosed WHO

1 in 15 dies

Cancer (hematopoietic) 100,000 every year ICMR

A mere 1000 survive

990000 die (no replacement Tx)

Alzheimer's 8.8 Million above 60 years ICMR

Menstrual Disorders 85% of women NFHS

Erectile Dysfunction 1 out of 10

25 out of 100 below 30 years NFHS

Osteoarthritis 15 million

Indians 22 to 39% of the world WHO

PROJECT ECONOMICS – PRECISION INFORMATICS DIAGNOSTICS CENTERS

BASIS FOR WORKING (MOST CONSERVATIVE)

The project commences around January 2024

First financial year, i.e., Jan – Mar 2024, 3 months, 30 centers per month
1500 centers per FY, 2nd, 3rd and 4th, 5th 1400
120 CR Indian Population
1 center for 200000 population, 6000 centers
Rs.10,00,000/- investment against equity by each center, with mandatory lock-in
period, at value decided at the appropriate time, with guaranteed buyback (if
required) at a profit
In addition, Rs.2,00,000/- investment by each center to have their own setup, as per
specifications given by INML
This 200000/- can take care of OVH of INML to a maximum extent
Out of Rs.15000 per person, the center retains 2000/- sends 13000/- to INML
For 1st F.Y., 3 months, 90 centers, only 10 people per center/3 month, 2nd F.Y., 1500
centers/20 center/month, 3rd F>Y., 3000 centers/20 per center/month, 4th F.Y., 4500
centers/20 center/month, 5th F.Y., 6000 centers/20 center/month.
To set up each center, Rs.150000/- is taken as ad-hoc cost.
To run operations, out of 13000/- INML gets, 7000 is set aside adhoc
An increase in prices will offset the increase in the cost of operations
From 4th FY equity will be returned for those who want. There are ample funds.
Guaranteed surplus from the first partial year of operation
Rs.10,00,000/- equity invested by each center is returned as Rs.15,00,000/- after
Mandatory lock-in
Each center makes around Rs.4,80,000/- each year, year after year, on a one-time
investment of just Rs.2,00,000/-
INML will be adding/launching several other products adding to the profits of
centers/INML.

Pricing
Rs. 15,000/- per head, around 25 test results with 80% accuracy
(In developed countries, this costs around Rs.1,50,000/- INR)
Rs. 45,000/- per person for 25 test results with 100% accuracy
(In developed countries, this costs around Rs.2,50,000/- INR)
Rs. 200,000/- per person for whole genome sequencing,
annotations and interpretations, and medical advice including
transplantation options.
(in developed countries, this costs around Rs.10,00,000/- INR)
Custom-made packages, fine-tuned to the individual needs, can be
designed.

Out of 200000 population, only 10%, i.e., 20000, might afford

Out of 20000, only .10% (20 citizens) might approach in a month initially.
Several years of assured work for the centers, @ 20 persons per month
INFLOW for INML (figures in Crores)

Through equity by centers 600.00

SPLIT UP – receipts per FY 9.00 150.00 150.00 150.00
141.00
Interest @ 10% - 15.00 30.00 45.00 14.10
Through Infrastructure/center 1.80 30.00 30.00 30.00 28.20
Through operations 1.17 468.00 936.00 1404.00 1872.00

TOTAL (A) 11.97 663.00 1146.00 1629.00 2055.30

OUTFLOW for INML (figures in Crores)

To run operations 0.63 252.00 504.00 756.00 1008.00

OVH 1 lakh per day 0.90 3.60 3.60 3.60 3.60
Misc. 1 lakh per day 0.90 3.60 3.60 3.60 3.60

TOTAL (B) 3.78 281.70 538.70 785.70 1036.35

SURPLUS/DEFICIT (A) – (B 8.19 381.30 608.00 843.30 1019.00

COST WORKING – RETURN ON INVESTMENT FOR THE CENTERS

Investment against equity (refundable with profit) 1000000

Investment against infrastructure 200000

TOTAL INVESTMENT 1200000

Return on equity investment after lock-in period 5,00,000

Equity buyback by INML @ 1500000/-

Returns through operations (2000 per person)

Jan – Mar 2024 10 per center @ 2000 per person 20000

April 24 – Mar 25 20 per center/month,2000 per person 480000
April 25 – Mar 26, 20 per center/month,2000 per person 480000
April 26 – Mar 27, 20 per center/month, 2000 per person 480000

 INML will be providing more opportunities to increase profits

 INML will introduce more packages
 INML will slowly branch into treatment based on diagnostics
 INML has plans to utilize this strong network for other high-end assignments
than diagnostics
 INML shall utilize the services of centers in its Medical-tourism venture,
enabling each center to make more profits
FUNDS REQUIREMENT / RETURNS TO THE INVESTOR/EXIT PLANS

INML invites Rs.90 Cr, as risk-free equity investment.

INML is ready to consider debt-based funding, depending on Investor needs
INML can pay up to 15% p.a., for debt-based funding, after 3-6 months of gestation
INML prefers Equity based funding, for obvious mutual benefits
INML is all set to launch PIC, the first of its kind, PAN India.
INML has crossed all risks related to research with Promoter’s funds
INML has the most valuable tangible/intangible assets to secure this investment
INML can issue equity shares to the tune of 90 Cr as per norms
INML can consider appointing investors on its Board
INML assures unprecedented capital appreciation
INML to come up with an IPO in 3 – 5 years, the most opportunistic time offered by
the market
INML has plans to launch Medical Tourism (land tied up) with value-additional
initiatives such as the Cell Donor database etc. simultaneously. Profitability will
increase manyfold.
INML is launching PIC first because of the very short gestation
INML can offer systematic exit (if debt-based) from 3rd year onwards
INML can offer systematic buyback (if equity based) from 3rd year onwards
INML offers, in the case of systematic buyback, to pay 180 Cr.
INML prefers long-standing relationships with investors so that during IPO investors
will gain in a very big way – the launch price shall be several times higher than the
cost at which investment is made. On a very cautious note, 90 Cr has the best
potential to grow up to 450 Cr. Or above.
PROFESSIONAL COLLABORATORS

Dr. A.K. Chandraker MD, MBChB Medical Director, Kidney, and Pancreas Tx
Harvard Medical School
Dr. A. Khanna MD, Ph.D., MBA, Professor of Surgery UCAL San Diego
FACS, FRCS Director Abdominal Transplants Program
Rady Children’s Hospital
Dr. P. Fontes, MD, FACS, Head Liver & Small Bowel Surgery, UPMC, PA
Dr. L. Valdivia Experimental Surgery
Dr. Noriko Murase Stem Cell Tx
Dr. Angus Thomson Ph.D., D.Sc., Dendritic Cell Tx Therapy
Distinguished Professor of Surgery and Immunology
University of Pittsburgh
Dr. Si Pham Cardio Thoracic Surgeon, Transplant Surgeon Mayo Clinic
Dr. H.R. Rilo MD., Professor, Department of Surgery, University of Arizona
Director Center for Cellular Transplant & Comprehensive
Pancreatitis Center, University of Arizona
Dr. Andreas Knoflach Faculty of Internal Medicine and Nephrology
Birmensdorferstr. Zurich, Switzerland
Dr. Colm Magee Renal Tx Boston MA
Dr. M. Denton Renal Tx & Medicine
Mr. Naren Renganathan MBA Senior Manager, Haemonetics Corp.,
Blood Components
Hemopheresis, Partitioning Instrumentation
Ms. R. Parthasarathy, ICWAI, FCA, Finance, USA
SALIENT FEATURES

Nil debts company.

Committed promoter with an international presence.
Ever growing population of India providing the best opportunity
1st of its kind in India combines 2 emerging & futuristic medicine fields in the world
Assured clients for medical tourism, due to CMD’s international presence.
Very short gestation, just about 3 months
Industry’s best break even
Once launched, self-financing and cash-rich
Once launched, ‘Value Addition Ventures’ to follow
Potential to go for IPO at the first opportunity presented by the market
A few other ventures are in the pipeline, getting ready for launch
INML has plans to approach Government to make this diagnostics mandatory.
Beyond the “best in its class returns” to the investors